Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. (LXRP)

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Posts Strategic Company Update

Posted on January 10, 2020 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements from 2019 and an outlook … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Holds Key Position as Edible Cannabis Market Opens Wide

Posted on January 9, 2020 by MissionIR

Canada’s first nationally legal cannabis-infused edible products began hitting store shelves December 17, vastly broadening the market for products using the plant’s extracts Lexaria Bioscience has dedicated years of research to the development of its proprietary DehydraTECH technology, designed to … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented DehydraTECH™ Platform Increases CBD Tissue Absorption by 1,937%

Posted on January 8, 2020 by MissionIR

DehydraTECH™ drug delivery platform achieved a 319% higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation The technology can be used on the nicotine market, the pharmaceutical market, and the cannabinoid market No other company … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Continues Reaching New Milestones

Posted on December 20, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced further advances in its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article discussing the company reads, “Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focuses on Pioneering New Technologies

Posted on December 13, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved into its new head office … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names Senior Advisor to Outline Leadership Strategies

Posted on December 6, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, recently appointed Gregg Smith, founder of a New York-based culture-tech, venture investment firm, as senior advisor to … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Edible Drug Delivery Platform Even Faster

Posted on December 5, 2019 by MissionIR

Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause Lexaria’s DehydraTECH platform has generated numerous patents with more … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Drug Delivery Platform Proven to Enhance Absorption of Bioactive Compounds

Posted on December 4, 2019 by MissionIR

DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins Lexaria has 16 patents granted and over 60 patent applications pending worldwide DehydraTECH™ shown to facilitate rapid … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Set to Profit from FDA’s MRTP Pathway Announcement

Posted on November 26, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had authorized the marketing of eight … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced Technology Shows Rapid Onset of Action in Under 10 Minutes

Posted on November 21, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its development of additional enhancements for its industry-leading DehydraTECH(TM) platform that delivers THC onset of action in less than 10 minutes in human pilot testing. … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment